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Repirinast is a new, synthetic, disodium cromoglycate-like antiallergic agent for oral administration 
in humans. This study evaluated the safety, tolerability and pharmacokinetics of repirinast tablets in 
healthy Chinese volunteers. This was a phase I, open-label, randomized, single- and multiple-dose 
study. Subjects were assigned to receive a single dose of repirinast tablet at either 150, 300, or 450 mg, 
or multiple doses of 150 mg twice daily for 5 days. Plasma samples were analyzed with LC-MS/MS. 
Pharmacokinetic parameters of active metabolite MY-1250 (deesterified repirinast) were calculated using 
non-compartmental analysis with WinNonlin software. Statistical analysis was performed using SPSS 
software. All adverse events (AEs) were mild and of limited duration. No serious adverse event (SAE), 
death or withdrawal from the study was observed. In the single-dose study, Cmax was reached at about 
0.75 hour, and the mean t1/2 was approximately 16.21 hours. Area under curve (AUC) and Cmax increased 
with dose escalation, but dose proportionality was not observed over the range of 150 to 450 mg. In the 
multiple-dose study, the steady-state was reached within 3 days with no accumulation. Repirinast tablet 
was well tolerated in healthy Chinese subjects.
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INTRODUCTION
Repirinast is a new, synthetic, disodium cromoglycate-
like, antiallergic agent for oral administration in humans 
and has been marketed in Japan since 1987 for the 
treatment of asthma. (Miyamoto et al., 1986; Takahashi et 
al., 1986; Takishima et al., 1986). Repirinast, as a prodrug, 
is immediately hydrolyzed to the active metabolite MY-
1250 (deesterified repirinast) after oral administration. The 
metabolite MY-1250 is pharmacodynamically active as it 
prevents the IgE-mediated allergic response by inhibiting 
the release of mediators triggered by antigen-antibody 
complexes (Yamada et al., 1988). Marketed as Romet®, 
repirinast was first developed by Mitsubishi Chemical 
Corporation in Japan. It was reported that repirinast was 
absorbed rapidly and hydrolyzed to active metabolite MY-
1250 after administration of a single 150 mg dose with 
the Cmax attained within approximately 2 hours. In urine, 
20.25% metabolite was MY-1250 and 2.7% was other 
active metabolite within 24 hours of oral administration. 
No accumulation appeared upon repeated doses.
An oral formulation of repirinast (150 mg tablets) 
was developed in China. Although the pharmacokinetics 
of repirinast in Japanese and Caucasian subjects has 
been reported (Iwamoto et al., 1986; Takagi et al., 
1989; Asamoto et al., 1989; Beermann et al., 1992), no 
pharmacokinetic data of repirinast in Chinese subjects is 
available. In this paper, the pharmacokinetics, safety and 
tolerability of repirinast tablets after single and multiple 
doses in healthy Chinese subjects are reported for the first 
time. The study was performed at the Second Affiliated 
Hospital of Soochow University (Suzhou, China) in 2015.
MATERIAL AND METHOD
Drug and reagents
Three doses (150 mg, 300 mg and 450 mg) of 
repirinast tablets (Batch: 201307012, Specifications: 
150 mg/tablet) for single and multiple doses were 
made.  Repir inas t  (Batch:  20130601D,  pur i ty : 
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99.8%) and MY-1250 reference substance (Batch: 
20140501D, purity: 99.3%) were obtained from 
Shanghai Cares Biotechnology Co., Ltd. (Shanghai, 
China). Levetiracetam reference substance (internal 
standard, IS, Batch: 201308-2, purity: 99.8%) was 
obtained from Zhejiang Huahai Pharmaceutical Co., Ltd 
(Linhai, China). HPLC-grade methanol was purchased 
from Merck KGaA Company (Darmstadt, Germany). 
Analytical grade ammonium acetate and ammonia 
hydroxide were purchased from Sinopharm Chemical 
Reagent Co., Ltd (Shanghai, China). Analytical grade 
hydrochloric acid was purchased from Shanghai 
Lingfeng Chemical Reagent Co., Ltd. (Shanghai, 
China). Distilled water was produced by a Milli-Q water 
purification system (Millipore, Bedford, USA).
Instruments
HPLC was performed using a 1200 Series device 
(Agilent Technologies, Palo Alto, CA, USA). Mass-
spectrometric detection was performed on an API 4000 
triple-quadrupole instrument (ABI-SCIEX, Ontario, 
Canada). 
Subjects
Healthy Chinese volunteers, aged 19-45, with a body 
mass index (BMI) of 19-24 kg/m2 and a body weight of 
more than 50 kg were eligible for inclusion in the study. 
Subjects were ascertained to be healthy through medical 
interview, physical examination, checking of vital signs, 
clinical laboratory tests (e.g. haematology, blood chemistry 
and urinalysis) and a 12-lead ECG test within 2 weeks 
before the first dosing of the study medication. Female 
subjects had to be using double barrier contraception or 
surgically sterilized. 
Persons were excluded from the study if they were: 
infected with hepatitis B or C virus or HIV or Syphilis; 
pregnant or breastfeeding; had a history of pulmonary, 
cardiovascular, neurological, psychiatric, endocrine or 
coagulation disorders; had renal or hepatic disease or any 
physical attributes that may influence the trial results; 
were medicated or using drugs of any kind in the two 
week period before the start of the study; had a history of 
abusing drugs or alcohol; had a history of smoking more 
than five cigarettes per day or equivalent; had participated 
in another drug study or donated blood in the three month 
period prior to this study.
The study was performed in accordance with the 
principles of the Declaration of Helsinki and Good Clinical 
Practice (GCP) in China. The study protocol was reviewed 
and approved by the Independent Ethics Committee of 
the Second Affiliated Hospital of Soochow University 
(approval numbers: 2013/35). All subjects provided 
written informed consent prior to entering the study.
Study design
This was a phase I, open-label, randomized, 
single and multiple-dose study. Twenty subjects were 
randomized to group 1 or group 2 (5 females and 5 males 
in each group). The subjects were hospitalized at 8:00 pm 
the night before dosing and required to fast overnight 
(10 h). Throughout the sequential single-dose and 
multiple-dose trials, repirinast tablets were administrated 
in the fasting state. After the trial, the subjects were 
released and visited the clinic for a test of vital signs, 
12-lead ECG, physical examination, and other routine 
laboratory tests. Additional laboratory tests were ordered 
by the principle investigator. 
Single dose administration
The single dose of repirinast tablet was 150 mg, 
300 mg or 450 mg once daily. On day 1 and day 8, 
subjects in group 1 were randomly assigned to receive 
a single oral administration of either 300 mg or 450 mg 
repirinast tablets. Subjects in group 2 received a single oral 
administration of 150 mg repirinast tablet on day 1. In the 
single dose study, subjects were required to fast overnight 
(10 h) before dosing. Water intake was prohibited within 
the 2 h following drug administration and a standard lunch 
was served 4 h after dosing. Blood samples (3 mL each) 
were collected in heparinized vacutainers pre-dose (0 h) 
and 10 min, 20 min, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 
4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h after dosing. During 
the study, blood samples were separated by centrifugation 
at 3200 × g at 4 °C for 10 min. All plasma samples were 
stored at -30 °C until analysis.
Multiple dose administration
After the single-dose phase from day 1 to 3, subjects 
from group 2 were assigned to receive 150 mg of repirinast 
tablet every 12 h from day 3 to day 7. Subjects were 
required to fast overnight (10 h) before the first (day 1) and 
last (day 8) dosing, and to fast 1 hour every 12 h before 
dosing from day 3 to day 7. On days 6, 7, and 8, predose 
blood samples (3 mL each) were collected prior to the 
morning dose to evaluate the achievement of steady state 
condition. On day 8, blood samples were collected predose 
(0 h) and at the same time points as in the single-dose study 
to 48 h after dosing. All the other experimental conditions 
were in consistent with those in the single dose phase.
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All of the subjects were hospitalized in the phase I 
unit ward of the Second Affiliated Hospital of Soochow 
University during the study. The subjects were required to 
refrain from smoking, alcohol and caffeinated beverages. 
Strenuous exercise was not allowed on each dosing day. 
Medications (including vitamins, herbal supplements and 
traditional Chinese medicines) were not permitted.
Analytical methods
Plasma concentrations of MY-1250 (the active 
metabolite of repirinast) were determined using the liquid 
chromatography-tandem mass spectrometry (LC-MS/
MS) method developed in our lab (Huang et al., 2017). 
This analytical method for analyzing the plasma consists 
of the following steps: 204 µL of pretreated plasma, 
50 µL of 400 ng/mL I.S. (levetiracetam) working solution 
and 600 µL of methanol were vortexed in a 1.5 mL 
polypropylene tube for 1 min and centrifuged at 21,130 × g 
at 4 oC for 5 min. 400 µL of the supernatant was mixed with 
800 µL of water, and 50 µL mixture was injected into the 
LC-MS/MS system (API 4000, Applied Biosystem Sciex, 
Ontario, Canada). The analyte was separated on a C18 
column (ZORBAX Eclipse plus C18, 4.6 mm × 100 mm, 
3.5 µm) equipped with a Phenomenex C18 Security guard 
column and the analytical column was maintained at 35 
oC. Mobile phases were 6 mM ammonium acetate (0.02% 
ammonia hydroxide included) (A) and methanol (B). 
The following gradient conditions were used for a 50 μL 
sample injection and constant 800 μL/min flow rate: 0-8.5 
min A: B (75:25); 8.6-9.6 min A: B (5:95); 9.7-13 min 
A: B (75:25). Mobile phases were controlled into the 
mass spectrometry system between 2.0 - 10.5 min. The 
MS/MS was carried out in the positive ionization mode 
with MY-1250 and I.S. being identified by the multiple 
reactions monitoring (MRM) at m/z 286.1→198.2 and m/z 
171.3→126.2, respectively. The calibration curves were 
linear over the range of 2 ~ 1500 ng/mL for MY-1250. The 
LLOQ was 2 ng/mL. The intra- and inter-assay precisions 
were less than 15%. The result of extraction recoveries 
for MY-1250 ranged from 87.0% to 88.1%. The result 
of matrix effect for MY-1250 ranged from 99.2% to 
100.2%. The stock solution was stable for 24 h at ambient 
temperature and for at least 26 days at 2~8 oC. The plasma 
samples were stable for 6 h at ambient temperature, during 
the three freeze-thaw cycles and for at least 65 days at 
-30 oC. The post-preparative solution was stable for 6 h 
at ambient temperature and for 40 h in the autosampler at 
4 oC. Low-, medium-, and high-quality control samples (4, 
80, 1200 ng/mL) were analyzed with the study samples to 
ensure the quality of analysis. 
Safety and tolerability evaluation
Adverse events (AEs), physical examinations, 
clinical laboratory tests, 12-lead ECGs and vital signs 
were monitored for safety and tolerability assessment. The 
relationship of AEs to the study drugs were graded as not 
related, probably not related, possibly related, probably 
related or definitely related by the investigators. All 
adverse events were coded using the Medical Dictionary 
for Regulatory Activities (MedDRA®).
Pharmacokinetic and statistical analysis
Pharmacokinetic analysis was performed with 
WinNonlin software (Version 6.3, Pharsight Corporation, 
Mountain View, CA, USA), utilizing non-compartmental 
analysis. The maximum plasma concentration (Cmax) 
and time to Cmax (tmax) were directly obtained from 
the concentration-time curves. The terminal-phase 
elimination half-life (t1/2) was calculated as 0.693/λz, 
where λz was the slope of the apparent elimination phase 
of the natural logarithmic (ln) transformation of the 
plasma concentration-time curve, which was estimated 
using liner regression. The area under the plasma 
concentration-time curve from time zero to t (AUC0–t), 
where t is the time of last measurable sample, was 
calculated according to the linear trapezoidal rule. The 
AUC from time zero to infinity (AUC0–∞) was estimated 
as AUC0–t+Ct/λz, where Ct was the plasma concentration 
of the last measurable sample. Apparent total clearance 
(Cl/F) was calculated as Dose/AUC0–∞ or Dose/AUCss 
and apparent total volume of distribution (Vz/F) was 
calculated as CL/λz. Attainment of steady state by day 8 
was evaluated by regressing the natural logarithmic (ln) 
transformation of trough concentrations on day 6, 7 and 
8 over time. The steady state was attained if the slope 
was not statistically different from zero. The steady state 
AUCs (AUCss) over the dosing interval (τ=12 h) and Cavg 
(AUCss/τ) were calculated. The degree of fluctuation (DF) 
was calculated as (Cmax–Cmin)/Cavg. Accumulation ratios 
were defined as the steady-state AUC0–τ to the single-dose 
AUC0-τ ratio or the steady state Cmax to the single dose 
Cmax ratio, namely, RAUC = AUC0–τ (steady state)/AUC0–τ 
(single-dose) (τ=12 h) and RCmax=Cmax (steady state)/Cmax 
(single dose), respectively.
Statistical analysis was performed using SPSS 
software (version 17.0, SPSS, Inc, Chicago, IL, USA). 
The results are expressed as the mean ± SD. Prior to the 
analysis, dose-dependent parameters (Cmax and AUC) 
were determined using natural logarithms of individual 
values. For the exploration of dose proportionality, the 
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slope β and 90% confidence intervals (CIs) obtained from 
the power model as ln(AUC or Cmax) = α + β × ln (dose) 
were computed by covariance (ANOVA). The regression 
coefficient was significant at level 0.1. The pre-defined 
criterion was set as (0.80, 1.25) and (0.75, 1.33) for AUC 
and Cmax, respectively. The criterion interval resulted in 
the value of (0.80, 1.20) and (0.74, 1.26) for AUC and 
Cmax, respectively. The differences in pharmacokinetic 
parameters among dose groups were compared using the 
analysis of t-test, with the exception of tmax, for which 
the non-parametric test (NPT) was used. Statistical 
comparisons between pharmacokinetic parameters of 
single and multiple doses were performed by the paired 
t-test. The differences in Cmin on day 6, 7, and 8 were 
compared using ANOVA to determine whether the steady 
state was reached in the multiple dose study.
RESULTS
Subjects
A total of 20 healthy subjects (10 males and 10 
females) were enrolled in the study. The randomization 
scheme of subjects is shown in Table I. No subject dropped 
out during the study. There were no significant differences 
among the 20 subjects with regard to age, height, weight, 
or body mass index (Table II). 
Pharmacokinetic assessment
Single-dose pharmacokinetics 
The mean plasma concentration-time curves after 
oral administration of 150, 300, or 450 mg repirinast 
tablets are shown in Figure 1, the pharmacokinetic 
parameters are presented in Table III. The results indicate 
that repirinast was absorbed rapidly, with a median tmax 
0.75 h of active metabolite MY-1250 across all of the 
dose cohorts. After reaching peak exposure, the plasma 
disposition of MY-1250 had a mean t1/2 of 16.21 h, 
which was independent of dose. The mean oral apparent 
total plasma clearance (Cl/F) and Vz/F of MY-1250 
were 164.4 L/h and 3296 L, 202.2 L/h and 4555 L, and 
237.5 L/h and 5269 L for the 150, 300, and 450 mg dose 
cohorts, respectively. Over the dose range of 150 to 450 
mg, the mean Cmax increased from 308.9 to 441.7 ng/mL, 
the AUC0-t increased from 937.0 to 1955 h·ng/mL and 
the AUC0-∞ increased from 1032 to 2272 h·ng/mL. The 
criterion intervals were (0.74, 1.26) for Cmax and (0.80, 
1.20) for AUC. However, the mean slopes (90% CIs) 
were 0.373 (0.075, 0.672) for Cmax, 0.665 (0.397, 0.933) 
for AUC0-t, and 0.679 (0.404, 0.955) for AUC0-∞. The 90% 
CIs for the ratio of dose-normalized of Cmax and AUC 
indicated that there was no apparent dose-proportional 
relationship over the range of 150 to 450 mg. The tmax and 
t1/2 were dose-independent (P>0.05).
TABLE I - The randomization scheme of subjects
Subject day1 day2 day 3 - day 7 day8
group 1 
(N=10)
single-dose 
300 mg or 450 mg
- - single-dose 
300 mg or 450 mg
group 2 
(N=10)
single-dose 
150 mg
- multiple-dose  
150 mg twice daily
single-dose 
150 mg
TABLE II - Subject demographics, mean ± SD (range)
Characteristic 
Single-dose Single-dose & Multiple-dose
300 mg & 450 mg 150 mg
n 10 10
Gender
male 5 5
female 5 5
Age (y) 23 ± 2 (21-27) 26 ± 2 (22-28)
Bodyweight (kg) 56.7 ± 4.6 (50.0-64.0) 58.1 ± 7.5 (51.0-76.0)
Height (cm) 164.2 ± 5.8 (158.0-177.0) 165.8 ± 7.6 (154.0-179.0) 
BMI (kg/m2) 21.0 ± 1.7 (19.2-23.4) 21.1 ± 1.3 (19.5-23.7)
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Multiple -dose pharmacokinetics
The mean plasma concentration-time curves of 
MY-1250 following multiple dose administration of 
150 mg repirinast tablets are presented in Figure 2, 
the pharmacokinetic parameters are presented in Table 
IV. Attainment of steady state was achieved by day 6 
because, per our analysis plan, the regression slope of 
the natural logarithmic (ln) transformation of trough 
concentrations on day 6, 7, and 8 over time was not 
statistically different from zero. The mean steady-state 
t1/2 was 13.83 ± 5.26 h, which is comparable to the t1/2 of a 
single dose (13.83 ± 7.51 h). The accumulation index was 
1.078 (90% CI, 0.833~1.324) based on the AUC0–t, and 
0.849 (90% CI, 0.545~1.152) based on Cmax, indicating 
that there was no further accumulation of repirinast after 
multiple administrations. The Cl/F, Vz/F, tmax and t1/2 
showed no significant difference between the first and 
the last dose. 
Safety and tolerability assessment
The only adverse event observed during the course 
of this study was elevated alanine aminotransferase 
(1/20, 5%), which was observed in one subject after 
administration of 150 mg repirinast tablets every 
12 h for 5 days. This is a known adverse reaction to 
repirinast and was likely related to the investigational 
drug.
The reported AE was mild or moderate in intensity 
and there were no SAEs, deaths or withdrawals. The 
subject recovered without medication or other treatment. 
There were no abnormal vital signs after treatment with 
repirinast tablets. When compared to baseline values 
acquired in the screening period, there were no clinically 
significant changes in the ECG data. Therefore, repirinast 
tablet was shown to be safe and well tolerated in healthy 
Chinese subjects.
FIGURE 1 - Mean plasma concentration-time curves of MY-1250 in healthy Chinese subjects after a single oral administration of 
repirinast tablet 150, 300 or 450 mg (mean ± SD).
TABLE III - Main pharmacokinetic parameters of MY-1250 after a single oral dose of repirinast tablet (mean ± SD)
Parameter 150 mg (n=10) 300 mg (n=10) 450 mg (n=10)
Cmax (ng/mL) 308.9 ±141.8 363.6 ±149.2 441.7 ± 139.6
tmax (h) 0.75 (0.50-3.00) 0.75 (0.50-1.50) 1.00 (0.50-1.50)
AUC0-t (h·ng/mL) 937.0 ± 330.8 1492 ± 534 1955 ± 902
AUC0-∞ (h·ng/mL) 1032 ± 310.1 1720 ± 632 2272 ± 1212
t1/2 (h) 13.83 ± 7.51 17.27 ± 11.72 17.54 ± 14.67
Cl/F (L/h) 164.4 ± 75.9 202.2 ± 94.8 237.5 ± 91.6
Vz/F (L) 3296 ± 2144 4555 ± 2670 5269 ± 3407
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DISCUSSION
In this study, the pharmacokinetics and safety of 
repirinast tablets in healthy Chinese volunteers is reported 
for the first time. This study was divided into two parts: 
single and multiple dose studies. 
In the single dose study, Cmax and AUC increased 
with dose escalation, but dose proportionality was not 
observed over the range of 150 to 450 mg. The values 
of tmax and t1/2 were dose-independent. The mean t1/2 of 
repirinast tablet was similar across all doses in the present 
study. The tmax of repirinast tablets was similar to values 
reported in previous studies (Beermann et al., 1992; 
Schaefer et al., 1993) and by the Romet® label. We report a 
mean t1/2 that is comparable to the report by Schaefer, H.G 
(Schaefer et al., 1993) and the Romet® label, but longer 
than the study of Beermann et al. (1992).
In this study, the 150 mg dose cohort after overnight 
fasting (5 males and 5 females), Cmax and AUC0-48 h of active 
metabolite MY-1250 were 308.9 ± 141.8 ng/mL and 937.0 
± 330.8 h·ng/mL. However, the Romet® label reported the 
Cmax and AUC of 150 mg Romet® after overnight fasting 
(16 males) as 169 ± 27 ng/mL and 892 h·ng/mL. Beermann 
et al. (1992) reported the geometric mean Cmax and AUC0-12 
FIGURE 2 - Mean plasma concentration-time curves of MY-1250 in healthy Chinese subjects following multiple doses of 150 mg 
repirinast tablet every 12 h for 5 days (mean ± SD).
TABLE IV - Main pharmacokinetic parameters of MY-1250 in healthy Chinese subjects following multiple doses of 150 mg repirinast 
tablet every 12 h for 5 days (mean ± SD)
Parameter single dose 
(d1)
multiple dose  
(d8)
Cmax (ng/mL) 308.9 ± 141.8 216.0 ± 119.3
tmax (h) 0.75 (0.50-3.00) 0.75 (0.50-2.50)
AUC0-t (h·ng/mL) 937.0 ± 330.8 929.7 ± 344.5
AUC0-∞ (h·ng/mL) 1032 ± 310 1021 ± 365
t1/2 (h) 13.83 ± 7.51 13.83 ± 5.26
Vz/F (L) 3296 ± 2144 3160 ± 1558
Cl/F (L/h) 164.4 ± 75.9 170.6 ± 75.7
Cavg (ng/mL) - 51.51±13.49
AUCSS (h·ng/mL) - 618.1 ± 161.9
DF - 362.9 ± 139.0
Rcmax - 0.849 ± 0.523
RAUC - 1.078 ± 0.424
tmax is shown as median (range); DF, degree of fluctuation.
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h of 150 mg (12 males) as 138 ng/mL and 307 h·ng/mL. In 
this study, the Cmax and AUC0-48 h of active metabolite MY-
1250 in the 300 mg dose and the 450 mg dose were 363.6 ± 
149.2 ng/mL and 1492 ± 534 h·ng/mL, 441.7 ± 139.6 ng/
mL and 1955 ± 902 h·ng/mL, respectively. Beermann et 
al. (1992) reported the geometric mean Cmax and AUC0-12 
h of 300 mg dose and 450 mg dose as 191 ng/mL and 502 
h·ng/mL, 241 ng/mL and 719 h·ng/mL, respectively. In 
this study, the mean clearance and volume of distribution 
of active metabolite MY-1250 was 164.4 ± 75.9 L/h and 
3296 ± 2144 L, 202.2 ± 94.8 L/h and 4555 ± 2670 L, 237.5 
± 91.6 L/h and 5269 ± 3407 L in 150 mg, 300 mg and 450 
mg dose, respectively. Beermann et al. (1992) reported 
the geometric mean clearance of active metabolite MY-
1250 as 28.10 L/h, 26.4 L/h and 25.50 L/h in 150 mg, 300 
mg and 450 mg dose, respectively. Schaefer et al. (1993) 
reported the mean clearance of active metabolite MY-
1250 in a 300 mg dose as 14.88-18.18 L/h. The difference 
between the studies may be due to the differences in the 
formulation, release of the drug from the tablets tested, 
race, sample size, gender and subject variability.
In the multiple-dose study, ten subjects (5 males and 
5 females) in group 2 received 150 mg repirinast tablets 
every 12 h for 5 days in the fasting state. There was no 
difference in Cmin-ss was found by ANOVA analysis. The 
tmax and t1/2 showed no difference between the first and the 
last dose. The steady-state was achieved within 3 d after 
twice daily dosing of 150 mg repirinast tablets. There was 
no accumulation after repeated doses of 150 mg every 12 
h for 5 days. The mean t1/2 was similar to that of the single-
dose study, indicating that the elimination rate of repirinast 
did not change during repeated administrations. 
The safety evaluation during the study demonstrated 
that repirinast tablet was well tolerated in healthy Chinese 
volunteers over the studied dose range. The only major 
adverse event was elevated alanine aminotransferase 
(1/20, 5%), which was observed in one subject after 
administration of 150 mg repirinast tablets every 12 h for 
5 days. This is a normal drug adverse reaction to repirinast 
and was likely related to the investigational drug. The 
reported AEs were mild and transient, and the subject 
recovered without any medication or further treatments. 
CONCLUSIONS
This study demonstrated the single and multiple dose 
pharmacokinetics of repirinast tablet and its safety profile 
in healthy Chinese volunteers. Repirinast, as a prodrug, 
is immediately hydrolyzed to the active metabolite, MY-
1250 (deesterified repirinast). The Cmax and the AUC 
of MY-1250 increased with dose escalation, but dose 
proportionality was not observed over the range of 150 to 
450 mg. The steady state was achieved within 3 days of 
twice daily dosing with the 150 mg repirinast tablet. There 
was no accumulation after multiple administrations. The 
repirinast tablet was well tolerated in healthy Chinese 
volunteers over the studied dose range.
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